Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings
Acta Neurologica Scandinavica Dec 12, 2017
Tsai JJ, et al. - The researchers examined the clinical efficacy and safety of perampanel as an adjunctive treatment for epileptic seizures. Perampanel tolerability could be improved by slow titration (2 mg every 2-4 weeks). Bedtime administration of perampanel could mitigate somnolence and dizziness. Regarding the potential for behavioral changes and close monitoring, counseling was recommended.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries